XK
BOLD

Xact Kapitalforvaltning’s Audentes Therapeutics, Inc BOLD Stock Holding History

Xact Kapitalforvaltning’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,400
Closed -$264K – 1442
2019
Q3 		$264K Hold
9,400
– – 0.01% 1263
2019
Q2 		$356K Buy
+9,400
New +$361K 0.01% 1122

Other funds holding BOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Xact Kapitalforvaltning's BOLD Position: Q4 2019 in Review

Xact Kapitalforvaltning sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 9,400 shares — an estimated $264K sold.

Xact Kapitalforvaltning first reported a position in BOLD in Q2 2019 and held it in 2 quarters. The position peaked at $356K in Q2 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

  • Xact Kapitalforvaltning reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 9,400 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $264K.
  • Xact Kapitalforvaltning first reported a position in Audentes Therapeutics, Inc in Q2 2019 and held it in 2 quarters.
  • Xact Kapitalforvaltning's Audentes Therapeutics, Inc position peaked at $356K in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q4 2019, filed 14 Feb 2020.